Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
64 studies found for:    "Mastocytosis"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Conditions: Smouldering Systemic Mastocytosis;   Indolent Systemic Mastocytosis;   Cutaneous Mastocytosis With Handicap;   Mastocytosis
Interventions: Drug: masitinib (AB1010);   Drug: placebo
2 Active, not recruiting Treatment of Indolent Systemic Mastocytosis With PA101
Conditions: Mastocytosis;   Systemic Mastocytosis;   Indolent Systemic Mastocytosis
Interventions: Drug: PA101;   Drug: Placebo
3 Recruiting Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
Conditions: Aggressive Systemic Mastocytosis (ASM);   Systemic Mastocytosis With Associated Clonal Hematological Non-mast Cell Lineage Disease (SM-AHNMD);   Mast Cell Leukemia (MCL);   Smoldering Systemic Mastocytosis (SSM);   Indolent Systemic Mastocytosis (ISM) [ISM Subgroup Fully Recruited]
Intervention: Other: Interview
4 Recruiting Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis;   Associated Clonal Hematological Non-Mast-Cell Lineage Disease
Interventions: Drug: Ibrutinib;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
5 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Intervention: Drug: brentuximab vedotin
6 Completed Imatinib in KIT-negative Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Imatinib Mesylate
7 Recruiting Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Conditions: Aggressive Systemic Mastocytosis;   Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease;   Mast Cell Leukemia;   Relapsed or Refractory Myeloid Malignancies
Intervention: Drug: BLU-285
8 Recruiting Mast Cell Connect: A Registry for Patients With Mastocytosis
Condition: Mastocytosis
Intervention:
9 Recruiting Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Cladribine and pegylated interpheron alpha-2a
10 Terminated
Has Results
Obatoclax for Systemic Mastocytosis
Conditions: Leukemia;   Systemic Mastocytosis
Intervention: Drug: Obatoclax Mesylate
11 Completed Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals
Conditions: Atopic Dermatitis;   Healthy;   Mastocytosis
Intervention:
12 Completed Efficacy and Safety of TF002 in Cutaneous Mastocytosis
Condition: Cutaneous Mastocytosis
Intervention: Drug: TF 002
13 Completed Cause and Natural Course of Pediatric-Onset Mastocytosis
Condition: Mastocytosis
Intervention:
14 Completed Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
Conditions: Leukemia;   Systemic Mastocytosis
Intervention: Drug: Ontak (Denileukin Diftitox)
15 Completed
Has Results
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: RAD001 (Everolimus)
16 Recruiting Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Procedure: Mastocytosis diagnosis
17 Completed Characteristics of Mast Cells in Mastocytosis
Condition: Mastocytosis
Intervention:
18 Active, not recruiting Midostaurin in Indolent Systemic Mastocytosis
Condition: Indolent Systemic Mastocytosis
Intervention: Drug: Midostaurin,
19 Completed Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
Conditions: Mastocytosis;   Anaphylaxis
Intervention:
20 Completed The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Condition: Mastocytosis
Intervention: Drug: injections

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years